CN1438989A - 新的无定形盐酸舍曲林 - Google Patents

新的无定形盐酸舍曲林 Download PDF

Info

Publication number
CN1438989A
CN1438989A CN01812018A CN01812018A CN1438989A CN 1438989 A CN1438989 A CN 1438989A CN 01812018 A CN01812018 A CN 01812018A CN 01812018 A CN01812018 A CN 01812018A CN 1438989 A CN1438989 A CN 1438989A
Authority
CN
China
Prior art keywords
sertraline hydrochloride
amorphous
solvent
suitable solvent
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01812018A
Other languages
English (en)
Chinese (zh)
Inventor
B·贺拉
A·罗哈吉
O·D·泰亚吉
Y·库马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CN1438989A publication Critical patent/CN1438989A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN01812018A 2000-05-26 2001-05-24 新的无定形盐酸舍曲林 Pending CN1438989A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN540DE2000 IN192343B (enExample) 2000-05-26 2000-05-26
IN540/DEL/2000 2000-05-26

Publications (1)

Publication Number Publication Date
CN1438989A true CN1438989A (zh) 2003-08-27

Family

ID=11097055

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01812018A Pending CN1438989A (zh) 2000-05-26 2001-05-24 新的无定形盐酸舍曲林

Country Status (11)

Country Link
US (1) US20040063792A1 (enExample)
EP (1) EP1289928A4 (enExample)
JP (1) JP2003534310A (enExample)
CN (1) CN1438989A (enExample)
AU (1) AU2001256595A1 (enExample)
BR (1) BR0111193A (enExample)
CA (1) CA2409856A1 (enExample)
CZ (1) CZ20023903A3 (enExample)
IN (1) IN192343B (enExample)
SK (1) SK17272002A3 (enExample)
WO (1) WO2001090049A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104189043A (zh) * 2007-12-23 2014-12-10 欧洲地中海股份有限公司 新的水飞蓟提取物、制备方法和应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
ATE354358T1 (de) 1999-12-21 2007-03-15 Teva Pharma Neue sertralinhydrochlorid polymorphe, verfahren zur herstellung und zur verwendung und diese enthaltende zusammensetzungen
EP1397343A1 (en) * 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
EP1499581A1 (en) 2002-04-29 2005-01-26 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
EP1626950A4 (en) 2003-05-23 2007-05-23 Transform Pharmaceuticals Inc SERTRALINZUSAMMENSETZUNGEN
EP1648854A1 (en) 2003-07-15 2006-04-26 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. Methods for preparing sertraline hydrochloride polymorphs
US7173153B2 (en) * 2003-07-15 2007-02-06 Recordati Industria Chimica E. Farmaceutica S.P.A. Sertraline hydrochloride form II and methods for the preparation thereof
US20060270859A1 (en) * 2005-01-27 2006-11-30 Santiago Ini Duloxetine HCl polymorphs
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
DK2665363T3 (da) * 2011-01-21 2020-01-20 Avery Dennison Corp Chlorhexidingluconat-indeholdende klæbemiddel
WO2012158483A2 (en) 2011-05-16 2012-11-22 Avery Dennison Corporation Adhesive containing microparticles
KR102242908B1 (ko) 2013-02-07 2021-04-20 애버리 데니슨 코포레이션 개선된 특성을 지니는 항미생물 접착제
WO2014151355A1 (en) 2013-03-15 2014-09-25 Avery Dennison Corporation Transparent cover dressing application system and inclusion of label strip
EP3789014A1 (en) 2014-06-05 2021-03-10 Avery Dennison Corporation Articles with active agent concentrated at the substrate contacting surface and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
JP2000026378A (ja) * 1998-07-03 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンの製法
DE69929462T2 (de) * 1998-11-27 2006-09-07 Teva Pharmaceutical Industries Ltd. Sertralin hydrochlorid form
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
TWI260315B (en) * 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104189043A (zh) * 2007-12-23 2014-12-10 欧洲地中海股份有限公司 新的水飞蓟提取物、制备方法和应用

Also Published As

Publication number Publication date
IN192343B (enExample) 2004-04-10
WO2001090049A1 (en) 2001-11-29
US20040063792A1 (en) 2004-04-01
JP2003534310A (ja) 2003-11-18
EP1289928A1 (en) 2003-03-12
SK17272002A3 (sk) 2003-05-02
AU2001256595A1 (en) 2001-12-03
EP1289928A4 (en) 2005-06-08
CA2409856A1 (en) 2001-11-29
BR0111193A (pt) 2003-07-29
CZ20023903A3 (cs) 2003-05-14

Similar Documents

Publication Publication Date Title
CN1438989A (zh) 新的无定形盐酸舍曲林
US7482463B2 (en) Amorphous form of esomeprazole salts
CN101679218B (zh) 晶体米诺环素碱及其制备方法
CN1086703C (zh) (r)－(－)－2{n－[4－(1,1－二氧化－3－氧代－2,3－二氢－苯并异噻唑－2－基)丁基]氨基甲基}苯并二氢吡喃的盐酸盐结晶
CN1368948A (zh) 普伐他汀钠盐晶体
CA2677563A1 (en) Amorphous form of an l-arginine salt of perindopril and processes for preparation thereof
US9199953B2 (en) Amorphous form of cabazitaxel and process for its preparation
WO2011004387A2 (en) Process for the preparation of dexlansoprazole polymorphic forms
CN1447812A (zh) 制造高纯度结晶(r,s)一头孢呋辛酯的方法
US20200361876A1 (en) Process for the preparation of diphenylpyrazine derivatives
BR0114728B1 (pt) Método para produzir uma acilfenilalanina
EP1185266A1 (en) Amorphous form of fexofenadine hydrochloride
CN1777586A (zh) 稳定的无定形樟脑磺酸氨氯地平、其制备工艺以及其口服给药的组合物
US20090202647A1 (en) Solid form of racemic rotigotine
CN109897009B (zh) 一种Apabetalone水合物晶型及其制备方法
US20060241305A1 (en) Amorphous form of losartan potassium
WO2023126865A1 (en) Solid forms of 1-{3-[3-(4-chlorophenyl) propoxy] propyl} piperidine hydrochloride and process for the preparation thereof
ES2398802T3 (es) Procedimiento mejorado para la preparación de fluvastatina y sales de la misma
AU2017343384B2 (en) Method for isolation and purification of naltrexone
WO2004039804A1 (en) Amorphous moxifloxacin hydrochloride
KR20160064139A (ko) 소듐 하이오데옥시콜레이트 (NaHDC)의 다형 형태 및 그의 제조 방법
CN110467539A (zh) 一种2，6-二甲基酪氨酸酯的拆分方法及其应用
WO2006056098A1 (fr) Processus de fabrication de dl-epherine, de pseudoephedrine ou de derives de ces composes et agents intermediaires
HK1091201A (en) Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
HK1058523A (en) Novel amorphous form of omeprazole salts

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned